ClinicalTrials.gg
CompletedNCT03873116APeX-JUpdated Jul 19, 2024Results posted

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan

A Phase 3 interventional study of BCX7353 capsules and BCX7353 capsules in Hereditary Angioedema, HAE, sponsored by BioCryst Pharmaceuticals. Completed at 10 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by BioCryst Pharmaceuticals · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies testing berotralstat in Angioedemas, Hereditary — 1 open to participants now, 2 under way, 2 of them phase 3. berotralstat · Angioedemas, Hereditary.

Enrollment
11th of 11
19 · median 58
Started
2018
with 2 others
Phase 3
4 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
11 of 11
BioCryst Pharmaceuticals

Among the 11 studies testing berotralstat in Angioedemas, Hereditary, this one is the 11th largest by enrollment, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 9th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies testing berotralstat in Angioedemas, Hereditary is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About berotralstat

berotralstat: first FDA approval 2020 (ORLADEYO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing berotralstat in Angioedemas, Hereditary, or all of them as a file.
02

Study summary

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE who live in Japan.

03

Conditions studied

  • Hereditary Angioedema, HAE

Keywords

  • BCX7353
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A clinical diagnosis of hereditary angioedema (HAE) Type 1 or Type 2, defined as having a C1-INH functional level and a C4 level below the lower limit of the normal (LLN) reference range, as assessed during the Screening period.
  • Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE
  • Subjects must be medically appropriate for on-demand treatment as the sole medicinal management for their HAE during the study.
  • Subjects must have a specified number of expert-confirmed attacks during the run-in period of 56 days from the Screening visit.
  • Acceptable effective
  • Written

Key Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Any medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study
  • Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study
  • Severe to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology
  • Use of C1-INH within 14 days or use of androgens or tranexamic acid within 28 days prior to the Screening visit for prophylaxis of HAE attacks, or initiation of these drugs during the study
  • Current participation in any other drug study or received another investigational drug within 30 days of the Screening visit
  • Prior enrollment in a BCX7353 study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    BCX7353 110mg once daily

    BCX7353 capsules administered orally once daily

    Drug: BCX7353 capsules

  • Experimental
    BCX7353 150mg once daily

    BCX7353 capsules administered orally once daily

    Drug: BCX7353 capsules

  • Placebo comparator
    Placebo

    Matching placebo oral capsules administered orally once daily

    Drug: Placebo oral capsule

Interventions

  • BCX7353 capsules administered orally once daily

  • BCX7353 capsules administered orally once daily

  • DrugPlacebo oral capsule

    Matching placebo capsules administered orally once daily

06

What researchers measure

Primary outcomes

  1. Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)

    The angioedema event rate and the treatment comparisons between each berotralstat dose and placebo in the rate of expert-confirmed angioedema events during the entire dosing period was analyzed using a negative binomial regression model. The number of expert-confirmed angioedema events was included as the dependent variable, the treatment was included as a fixed effect, the stratification variable (baseline monthly angioedema event rate) and study (for the combined study analysis) were included as covariates, and the logarithm of duration on treatment was included as an offset variable. The estimated rate of angioedema events for each treatment group, the treatment differences expressed as the angioedema event rate ratio (berotralstat) over placebo rate ratio), and their associated 95% confidence intervals (CIs) were provided from the negative binomial regression model.

    Time frame: 24 weeks

  2. Part 2: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE

    The safety data was assessed for the safety population for subjects who entered Part 2, and includes TEAEs that occurred in Part 1 and Part 2 for these subjects with a data cut-off date of 10-April-2020. TEAEs are defined as AEs that occurred on or after first dose of study treatment, whether in Part 1 or 2, and were assigned to the relevant treatment depending on when the TEAE began (Part 1 or Part 2 treatment). TEAEs were assessed for severity (graded) using the Division of Microbiology and Infectious Disease (DMID) criteria for grading AEs. TEAEs not covered by the DMID criteria were assessed as Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3) or Life-threatening (Grade 4).

    Time frame: Part 1: 24 weeks (Week 0 to 24 to 52), Part 2: 28 weeks (Week 24 to 52)

  3. Part 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat Administered QD Over a 52- to up to 104-week Administration Period in Subjects With HAE.

    The safety data was assessed for the safety population for subjects who entered Part 3, and includes TEAEs that occurred in Part 3 for these subjects.

    Time frame: Part 3: Week 52 to up to Week 104.

Secondary outcomes

  1. Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks.

    Assessment of number and proportion of days subjects had angioedema symptoms from expert-confirmed angioedema events during Part 1.

    Time frame: 24 weeks

  2. Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period

    The rate of expert-confirmed angioedema events for the effective treatment period gives an analysis of the efficacy of active treatment after berotralstat had reached steady-state concentrations, given the effective half-life of 150 mg berotralstat in Study BCX7353-106 (Study 106) of 89 hours.

    Time frame: Day 8 through to 24 weeks

  3. Part 1: Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire at Week 24 (Total Score)

    Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score).

    Time frame: Baseline and 24 weeks

  4. Part 2: To Assess the Effectiveness of Berotralstat Over a 24- to 52-week Period

    Monthly Attack Rate was defined as the total number of investigator-confirmed HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. The end of Month 6 was defined as the start of Part 2 treatment. For crossover subjects receiving active treatment following placebo, months were adjusted according to the date of the first dose of active treatment. Baseline investigator-confirmed attack rate was defined as the total number of investigator-confirmed HAE attacks experienced in the period between screening and first dose of study drug adjusted for the length of a month (defined as 28 days) and the number of days during that period.

    Time frame: 28 weeks (Week 24 to 52)

  5. Part 2: To Evaluate QoL Following Berotralstat Administration Over a 24- to 52-week Period.

    Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL is only validated for adults; however, data were collected on all adult and adolescent study subjects.

    Time frame: 28 Weeks (Week 24 to 52)

  6. Part 3: To Assess the Effectiveness of Berotralstat Over a 52- to up to 104-week Administration Period

    Adjusted subject-reported event rate was defined as (total number of adjusted subject-reported HAE events experienced in the period between the Week 52 visit and end of study \[or the last dose date/time in Part 3 + 24 hours for subjects who discontinued drug in Part 3\]) \* 28/(date of last dose in Part 3 - date of Week 52 visit + 1).

    Time frame: 52 weeks (Week 52 to 104)

  7. Part 3: To Evaluate QoL Following Berotralstat Administration Over a 52- to up to 104-week Period

    Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

    Time frame: 52 Weeks (Week 52 to 104)

  8. Part 3: To Evaluate Subject's Satisfaction With Berotralstat During 52- to 104-week Administration Period

    The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scales scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

    Time frame: 52 Weeks (Week 52 to 104)

07

Results

Posted Mar 4, 2021

Participant flow

Part 1
Participant flow — Part 1
MilestoneBerotralstat 110mg Once DailyBerotralstat 110mg QD, Followed by Berotralstat 150 mg QDBerotralstat 110mg QD After PlaceboBerotralstat 110mg QD, Followed by Berotralstat 150 mg QD, After PlaceboBerotralstat 150mg Once DailyBerotralstat 150mg QD After Placebo
Started332173
Completed332172
Not completed000001
Withdrew: Study drug discontinuation due to rash000001
Part 2
Participant flow — Part 2
MilestoneBerotralstat 110mg Once DailyBerotralstat 110mg QD, Followed by Berotralstat 150 mg QDBerotralstat 110mg QD After PlaceboBerotralstat 110mg QD, Followed by Berotralstat 150 mg QD, After PlaceboBerotralstat 150mg Once DailyBerotralstat 150mg QD After Placebo
Started331172
Completed330162
Not completed001010
Withdrew: Withdrawal by subject001000
Withdrew: Lab abnormality or ae000010
Part 3
Participant flow — Part 3
MilestoneBerotralstat 110mg Once DailyBerotralstat 110mg QD, Followed by Berotralstat 150 mg QDBerotralstat 110mg QD After PlaceboBerotralstat 110mg QD, Followed by Berotralstat 150 mg QD, After PlaceboBerotralstat 150mg Once DailyBerotralstat 150mg QD After Placebo
Started030161
Completed030151
Not completed000010
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryPart 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)

The angioedema event rate and the treatment comparisons between each berotralstat dose and placebo in the rate of expert-confirmed angioedema events during the entire dosing period was analyzed using a negative binomial regression model. The number of expert-confirmed angioedema events was included as the dependent variable, the treatment was included as a fixed effect, the stratification variable (baseline monthly angioedema event rate) and study (for the combined study analysis) were included as covariates, and the logarithm of duration on treatment was included as an offset variable. The estimated rate of angioedema events for each treatment group, the treatment differences expressed as the angioedema event rate ratio (berotralstat) over placebo rate ratio), and their associated 95% confidence intervals (CIs) were provided from the negative binomial regression model.

Time frame:
24 weeks
Reported as:
Mean · Angioedema event rate per 28 days
Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)
Angioedema event rate per 28 daysBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)1.961 ± 1.30211.089 ± 0.91682.734 ± 1.6359
Statistical analysis
  • Berotralstat 110mg Once Daily vs Placebo · negative binomial regression model · p = 0.181 · Negative binomial regression model: -24.6 · 95% CI -50.1 to 14.0
  • Berotralstat 150mg Once Daily vs Placebo · negative binomial regression model · p = 0.003 · Negative binomial regression model: -49.1 · 95% CI -67.5 to -20.4
PrimaryPart 2: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE

The safety data was assessed for the safety population for subjects who entered Part 2, and includes TEAEs that occurred in Part 1 and Part 2 for these subjects with a data cut-off date of 10-April-2020. TEAEs are defined as AEs that occurred on or after first dose of study treatment, whether in Part 1 or 2, and were assigned to the relevant treatment depending on when the TEAE began (Part 1 or Part 2 treatment). TEAEs were assessed for severity (graded) using the Division of Microbiology and Infectious Disease (DMID) criteria for grading AEs. TEAEs not covered by the DMID criteria were assessed as Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3) or Life-threatening (Grade 4).

Time frame:
Part 1: 24 weeks (Week 0 to 24 to 52), Part 2: 28 weeks (Week 24 to 52)
Reported as:
Count of participants · Participants
Part 2: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE
ParticipantsBerotralstat 110mg Once DailyBerotralstat 110mg QD After PlaceboBerotralstat 150mg Once DailyBerotralstat 150mg QD After PlaceboPlacebo
TEAE61726
Drug-related TEAE20302
SAE20000
Drug-related SAE00000
Grade 3 or 4 TEAE00101
Drug-related grade 3 or 4 TEAE00100
TEAE leading to interruption of study drug10200
TEAE leading to discontinuation of study drug00101
Investigator-identified rash (event of special interest)10201
GI abdominal related TEAE31311
GI abdominal related TEAE leading to discontinuation of study drug00000
PrimaryPart 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat Administered QD Over a 52- to up to 104-week Administration Period in Subjects With HAE.

The safety data was assessed for the safety population for subjects who entered Part 3, and includes TEAEs that occurred in Part 3 for these subjects.

Time frame:
Part 3: Week 52 to up to Week 104.
Reported as:
Count of participants · Participants
Part 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat Administered QD Over a 52- to up to 104-week Administration Period in Subjects With HAE.
ParticipantsBerotralstat 150mg Once Daily
TEAE6
Drug-related TEAE0
SAE1
Drug-related SAE0
Grade 3 or 4 TEAE1
Drug-related grade 3 or 4 TEAE0
TEAE leading to interruption of study drug0
TEAE leading to discontinuation of study drug0
Investigator-identified rash (event of special interest)0
GI abdominal related TEAE0
GI abdominal related TEAE leading to discontinuation of study drug0
SecondaryPart 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks.

Assessment of number and proportion of days subjects had angioedema symptoms from expert-confirmed angioedema events during Part 1.

Time frame:
24 weeks
Reported as:
Least squares mean · Proportion days with angioedema symptoms
Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks.
Proportion days with angioedema symptomsBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks.0.258 ± 0.05340.118 ± 0.05000.240 ± 0.0536
Statistical analysis
  • Berotralstat 110mg Once Daily vs Placebo · ANCOVA · p = 0.814 · Difference in least square means: 0.018 · 95% CI -0.143 to 0.179
  • Berotralstat 150mg Once Daily vs Placebo · ANCOVA · p = 0.120 · Difference in least square means: -0.122 · 95% CI -0.280 to 0.036
SecondaryPart 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period

The rate of expert-confirmed angioedema events for the effective treatment period gives an analysis of the efficacy of active treatment after berotralstat had reached steady-state concentrations, given the effective half-life of 150 mg berotralstat in Study BCX7353-106 (Study 106) of 89 hours.

Time frame:
Day 8 through to 24 weeks
Reported as:
Mean · Angioedema event rate per 28 days
Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period
Angioedema event rate per 28 daysBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period1.988 ± 1.34221.136 ± 0.95642.775 ± 1.6472
Statistical analysis
  • Berotralstat 110mg Once Daily vs Placebo · mixed-model repeated measures analysis · p = 0.188 · Mixed-model repeated measures analysis: 24.5 · 95% CI -14.7 to 50.3
  • Berotralstat 150mg Once Daily vs Placebo · mixed-model repeated measures analysis · p = 0.005 · Mixed-model repeated measures analysis: 47.6 · 95% CI 17.7 to 66.6
SecondaryPart 1: Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire at Week 24 (Total Score)

Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score).

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · AE-QoL Total Score Change from baseline
Part 1: Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire at Week 24 (Total Score)
AE-QoL Total Score Change from baselineBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
Part 1: Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire at Week 24 (Total Score)-9.47 ± 6.933-15.82 ± 6.4243.18 ± 6.832
Statistical analysis
  • Berotralstat 110mg Once Daily vs Placebo · mixed-model repeated measures analysis · p = 0.213 · Mixed-model repeated measures analysis: -12.65 · 95% CI -33.33 to 8.03
  • Berotralstat 150mg Once Daily vs Placebo · mixed-model repeated measures analysis · p = 0.061 · Mixed-model repeated measures analysis: -19.00 · 95% CI -39.00 to 0.99
SecondaryPart 2: To Assess the Effectiveness of Berotralstat Over a 24- to 52-week Period

Monthly Attack Rate was defined as the total number of investigator-confirmed HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. The end of Month 6 was defined as the start of Part 2 treatment. For crossover subjects receiving active treatment following placebo, months were adjusted according to the date of the first dose of active treatment. Baseline investigator-confirmed attack rate was defined as the total number of investigator-confirmed HAE attacks experienced in the period between screening and first dose of study drug adjusted for the length of a month (defined as 28 days) and the number of days during that period.

Time frame:
28 weeks (Week 24 to 52)
Reported as:
Mean · HAE attacks/28 days-change from baseline
Part 2: To Assess the Effectiveness of Berotralstat Over a 24- to 52-week Period
HAE attacks/28 days-change from baselineBerotralstat 110mg Once DailyBerotralstat 110mg QD After PlaceboBerotralstat 150mg Once DailyBerotralstat 150mg QD After Placebo
Month 6-0.487 ± 1.0661-0.686 ± 0.2872-0.863 ± 1.3000-1.386 ± 0.5951
Month 7-1.085 ± 0.8249-0.889 ± 0-1.395 ± 0.9127-1.403 ± 0.7948
Month 8-0.585 ± 0.5622—-1.395 ± 0.8016—
Month 9-0.418 ± 0.8910—-0.927 ± 0.7645—
Month 10-0.918 ± 1.0134—-0.733 ± 0.8068—
Month 11-0.585 ± 0.5622—-1.400 ± 0.9997—
Month 12-0.585 ± 1.0737—-0.900 ± 0.3925—
Month 13-0.757 ± 0.9729—-0.733 ± 1.3060—
SecondaryPart 2: To Evaluate QoL Following Berotralstat Administration Over a 24- to 52-week Period.

Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL is only validated for adults; however, data were collected on all adult and adolescent study subjects.

Time frame:
28 Weeks (Week 24 to 52)
Reported as:
Mean · AE-QoL score -change from baseline
Part 2: To Evaluate QoL Following Berotralstat Administration Over a 24- to 52-week Period.
AE-QoL score -change from baselineBerotralstat 110mg Once DailyBerotralstat 110mg QD After PlaceboBerotralstat 150mg Once DailyBerotralstat 150mg QD After Placebo
Week 24-4.9 ± 13.0-19.1 ± 0-19.5 ± 31.20 ± 0
Week 52-7.4 ± 9.4—-17.2 ± 30.6—
SecondaryPart 3: To Assess the Effectiveness of Berotralstat Over a 52- to up to 104-week Administration Period

Adjusted subject-reported event rate was defined as (total number of adjusted subject-reported HAE events experienced in the period between the Week 52 visit and end of study \[or the last dose date/time in Part 3 + 24 hours for subjects who discontinued drug in Part 3\]) \* 28/(date of last dose in Part 3 - date of Week 52 visit + 1).

Time frame:
52 weeks (Week 52 to 104)
Reported as:
Mean · HAE attacks per 28 days
Part 3: To Assess the Effectiveness of Berotralstat Over a 52- to up to 104-week Administration Period
HAE attacks per 28 daysBerotralstat 150mg Once Daily
Part 3: To Assess the Effectiveness of Berotralstat Over a 52- to up to 104-week Administration Period0.883 ± 1.1216
SecondaryPart 3: To Evaluate QoL Following Berotralstat Administration Over a 52- to up to 104-week Period

Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

Time frame:
52 Weeks (Week 52 to 104)
Reported as:
Mean · AE-QoL score -change from baseline
Part 3: To Evaluate QoL Following Berotralstat Administration Over a 52- to up to 104-week Period
AE-QoL score -change from baselineBerotralstat 150mg Once Daily
Week 52-11.11 ± 29.089
Week 60-13.24 ± 23.758
Week 72-17.38 ± 24.998
Week 84-11.63 ± 22.900
Week 96-20.40 ± 32.069
Week 104-18.93 ± 30.681
SecondaryPart 3: To Evaluate Subject's Satisfaction With Berotralstat During 52- to 104-week Administration Period

The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scales scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

Time frame:
52 Weeks (Week 52 to 104)
Reported as:
Mean · TSQM Global score -change from baseline
Part 3: To Evaluate Subject's Satisfaction With Berotralstat During 52- to 104-week Administration Period
TSQM Global score -change from baselineBerotralstat 150mg Once Daily
Week 6011.7 ± 37.15
Week 7213.6 ± 37.72
Week 8411.7 ± 34.44
Week 9618.8 ± 26.43
Week 10416.1 ± 23.77

Adverse events

Collected over Adverse Events (AEs) were assessed and recorded from the time that the Informed consent form was signed until the last follow-up visit, approximately 3 weeks following the last dose of study drug, or until the AE was resolved or the subject was in a clinically stable condition with regard to the AE. AEs were assigned to the relevant treatment depending on when the AE began; i.e., Part 1 or Part 2 and 3 treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Berotralstat 110mg Once Daily0/8 (0%)2/8 (25%)8/8 (100%)
Berotralstat 150mg Once Daily0/9 (0%)1/9 (11.1%)9/9 (100%)
Placebo0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
PneumoniaInfections and infestations1/80/90/6
Hereditary angioedemaCongenital, familial and genetic disorders1/80/90/6
Ankle fractureInjury, poisoning and procedural complications0/81/90/6
Fibula fractureInjury, poisoning and procedural complications0/81/90/6
Most frequent other events
Showing 10 of 51
Most frequent other events
EventBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
NasopharyngitisInfections and infestations3/84/94/6
Abdominal painGastrointestinal disorders2/82/90/6
CoughRespiratory, thoracic and mediastinal disorders2/80/90/6
InfluenzaInfections and infestations2/80/90/6
PruritusSkin and subcutaneous tissue disorders0/82/90/6
Back painMusculoskeletal and connective tissue disorders0/82/90/6
Abdominal discomfortGastrointestinal disorders1/80/91/6
ToothacheGastrointestinal disorders0/80/91/6
UrticariaSkin and subcutaneous tissue disorders0/81/91/6
Arthropod biteInjury, poisoning and procedural complications0/80/91/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Berotralstat 110mg Once DailyPart 1: Berotralstat 150mg Once DailyPart 1: PlaceboTotal
Mean47.3 ± 15.0337.3 ± 9.0542.3 ± 13.5242.1 ± 12.61
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Berotralstat 110mg Once DailyPart 1: Berotralstat 150mg Once DailyPart 1: PlaceboTotal
Female56516
Male1113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Berotralstat 110mg Once DailyPart 1: Berotralstat 150mg Once DailyPart 1: PlaceboTotal
American Indian or Alaska Native0000
Asian66618
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0101
Baseline expert-confirmed angioedema event rate
Baseline expert-confirmed angioedema event rate(participants)Part 1: Berotralstat 110mg Once DailyPart 1: Berotralstat 150mg Once DailyPart 1: PlaceboTotal
≥ 2 events/month2439
< 2 events/month43310
08

Study locations

10 sites
  • Study Site
    Chiba, Japan
  • Study Site
    Gunma, Japan
  • Study Site
    Hokkaido, Japan
  • Study Site
    Nagoya, Japan
  • Study Site
    Osaka, Japan
  • Study Center
    Saga, Japan
  • Study Site
    Saitama, Japan
  • Study Site
    Shimane, Japan
  • Study Site
    Shizuoka, Japan
  • Study Site
    Tokyo, Japan
09

References and documents

Publications

  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗
  • Ohsawa I, Honda D, Suzuki Y, Fukuda T, Kohga K, Morita E, Moriwaki S, Ishikawa O, Sasaki Y, Tago M, Chittick G, Cornpropst M, Murray SC, Dobo SM, Nagy E, Van Dyke S, Reese L, Best JM, Iocca H, Collis P, Sheridan WP, Hide M. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial. Allergy. 2021 Jun;76(6):1789-1799. doi: 10.1111/all.14670. Epub 2020 Dec 23. PubMed 33247955 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jul 2021, 30 months.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 30 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2019
First posted
Mar 13, 2019
StartActual
Dec 27, 2018
Primary completionActual
Jul 8, 2021
CompletionActual
Jul 8, 2021
Results first posted
Mar 4, 2021
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03873116
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Dec 27, 2018
Primary completion
Jul 8, 2021
Completion
Jul 8, 2021
Results posted
Mar 4, 2021
Last update
Jul 19, 2024

Study contacts

Isao Ohsawa
principal investigator · Saiyu Soka Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berotralstat

Start the discussion